ArticleAmerican journal of cancer research2025
Multivariate analysis and prediction model construction for distant metastasis of Acral Melanoma.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the pathological characteristics of Acral Melanoma (AM) patients and identify the factors influencing distant metastasis, while constructing a predictive model for distant metastasis-free survival (DMFS).
methodsConducted on 229 AM patients admitted to the Third People's Hospital of Bengbu and The First Affiliated Hospital of Anhui Medical University from January 1, 2012, to December 31, 2024. Data collected included gender, age, lesion location, initial diagnosis stage, trauma history, ulcer presence, Breslow thickness, mitotic rate, lactate dehydrogenase (LDH), albumin (Alb), and adjuvant therapy. DMFS was assessed through follow-up, with a deadline of March 31, 2025. Statistical analysis was performed to evaluate significant factors influencing distant metastasis.
resultsThe incidence of AM showed an increasing trend from 2012 to 2024. Of the 229 patients, 78 (34.06%) developed distant metastasis. The median follow-up period was 37 months, and 1-year, 3-year, and 5-year survival rates without distant metastasis were 93.45%, 74.24%, and 66.81%, respectively. Statistically significant factors affecting DMFS included initial diagnosis stage, ulcer presence, Breslow thickness, mitotic rate, LDH, and Alb levels (all P<0.05). Risk factors for distant metastasis included stage III at diagnosis, ulcer presence, lack of adjuvant therapy, elevated LDH, and low Alb levels.
conclusionsThe study identified key pathological factors influencing distant metastasis in AM patients. The constructed nomogram model demonstrated good predictive accuracy, with AUC values of 0.895 and 0.879 in the training and validation sets, respectively. This model can aid in the clinical screening of AM patients at risk for distant metastasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.